Table 2.
Genotype | Cases (n = 368) n (%) |
Controls (n = 368) n (%) |
p* | HWE Cases |
HWE Controls |
---|---|---|---|---|---|
5-HTTLPR (n = 698) | 0.286 | 0.323 | 0.1916 | ||
LL | 223 (62.3) | 231 (67.9) | |||
LS | 115 (32.1) | 94 (27.7) | |||
SS | 20 (5.6) | 15 (4.4) | |||
rs25531 (n = 685) | 0.988 | 0.795 | 0.641 | ||
AA | 227 (65.4) | 221 (65.4) | |||
AG | 108 (31.1) | 106 (31.4) | |||
GG | 12 (3.5) | 11 (3.2) | |||
5-HTTLPR-rs25531 haplotype (n = 685) | 0.688 | N/A | N/A | ||
L-A-L-A | 130 (37.4) | 136 (40.2) | |||
L-A-L-G | 76 (21.9) | 82 (24.3) | |||
L-A-S-A | 79 (22.8) | 71 (21.0) | |||
L-A-S-G | 2 (0.6) | Absent | |||
L-G-L-G | 12 (3.5) | 11 (3.3) | |||
S-A-S-A | 18 (5.2) | 15 (4.4) | |||
S-A-L-G | 30 (8.6) | 23 (6.8) | |||
STin2 VNTR (n = 687) | 0.203 | 0.090 | 0.440 | ||
10/10 | 26 (7.5) | 28 (8.8) | |||
10/12 | 126 (36.3) | 112 (35.3) | |||
12/12 | 189 (54.5) | 177 (55.9) | |||
9/9 | 5 (1.4) | Absent | |||
9/12 | 1 (0.3) | Absent | |||
rs1843809 (n = 686) | 0.003 | 0.009 | 0.537 | ||
TT | 105 (30.1) | 113 (33.5) | |||
TG | 150 (43.0) | 169 (50.2) | |||
GG | 94 (26.9) | 55 (16.3) | |||
rs1386494 (n = 685) | 0.06 | 0.956 | 0.007 | ||
GG | 210 (59.7) | 202 (60.7) | |||
GA | 124 (35.2) | 125 (37.5) | |||
AA | 18 (5.1) | 6 (1.8) | |||
rs34517220 (n = 685) | 0.945 | 0.557 | 0.913 | ||
AA | 90 (25.6) | 84 (25.1) | |||
AG | 170 (48.4) | 166 (49.7) | |||
GG | 91 (25.9) | 84 (25.2) | |||
rs4570625 (n = 683) | 0.574 | 0.787 | 0.229 | ||
GG | 88 (25.2) | 90 (26.9) | |||
GT | 177 (50.7) | 156 (46.7) | |||
TT | 84 (24.1) | 88 (26.4) |
5-HTTLPR, serotonin transporter linked polymorphic region; STin2 VNTR, serotonin transporter intron 2 variable number of tandem repeats; HWE, Hardy-Weinberg equilibrium; N/A, not applicable.
Value of p for association of each investigated polymorphism with IMDs.